M Gutiérrez-Valencia1,2, M Izquierdo3,4, M Cesari5,6, Á Casas-Herrero1,2,4, M Inzitari7,8, N Martínez-Velilla1,2,4. 1. Department of Geriatrics, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain. 2. IdiSNa, Navarra Institute for Health Research, Pamplona, Navarra, Spain. 3. Health Science Department, Public University of Navarra, Pamplona, Navarra, Spain. 4. CIBER of Frailty and Healthy Aging, Madrid, Spain. 5. Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. 6. Dipartimento di Scienze Cliniche e di Comunità, Università di Milano, Milan, Italy. 7. Parc Sanitari Pere Virgili, Barcelona, Catalonia, Spain. 8. Universitat Autònoma de Barcelona, Catalonia, Spain.
Abstract
AIMS: Frailty is a complex geriatric syndrome resulting in decreased physiological reserves. Frailty and polypharmacy are common in older adults and the focus of extensive studies, although little is known about the impact they may have on each other. This is the first systematic review analysing the available evidence on the relationship between frailty and polypharmacy in older adults. METHODS: Systematic review of quantitative studies. A comprehensive literature search for publications in English or Spanish was performed on MEDLINE, CINAHL, the Cochrane Database and PsycINFO in September 2017 without applying restrictions on the date of publication. Studies reporting any relationship between frailty and polypharmacy in older adults were considered. RESULTS: A total of 25 publications were included, all of them observational studies. Evaluation of Fried's frailty criteria was the most common approach, followed by the Edmonton Frail Scale and FRAIL scale. Sixteen of 18 cross-sectional analyses and five of seven longitudinal analyses demonstrated a significant association between an increased number of medications and frailty. The causal relationship is unclear and appears to be bidirectional. Our analysis of published data suggests that polypharmacy could be a major contributor to the development of frailty. CONCLUSIONS: A reduction of polypharmacy could be a cautious strategy to prevent and manage frailty. Further research is needed to confirm the possible benefits of reducing polypharmacy in the development, reversion or delay of frailty.
AIMS: Frailty is a complex geriatric syndrome resulting in decreased physiological reserves. Frailty and polypharmacy are common in older adults and the focus of extensive studies, although little is known about the impact they may have on each other. This is the first systematic review analysing the available evidence on the relationship between frailty and polypharmacy in older adults. METHODS: Systematic review of quantitative studies. A comprehensive literature search for publications in English or Spanish was performed on MEDLINE, CINAHL, the Cochrane Database and PsycINFO in September 2017 without applying restrictions on the date of publication. Studies reporting any relationship between frailty and polypharmacy in older adults were considered. RESULTS: A total of 25 publications were included, all of them observational studies. Evaluation of Fried's frailty criteria was the most common approach, followed by the Edmonton Frail Scale and FRAIL scale. Sixteen of 18 cross-sectional analyses and five of seven longitudinal analyses demonstrated a significant association between an increased number of medications and frailty. The causal relationship is unclear and appears to be bidirectional. Our analysis of published data suggests that polypharmacy could be a major contributor to the development of frailty. CONCLUSIONS: A reduction of polypharmacy could be a cautious strategy to prevent and manage frailty. Further research is needed to confirm the possible benefits of reducing polypharmacy in the development, reversion or delay of frailty.
Authors: Natali Jokanovic; Edwin C K Tan; Michael J Dooley; Carl M Kirkpatrick; J Simon Bell Journal: J Am Med Dir Assoc Date: 2015-04-11 Impact factor: 4.669
Authors: Marie Herr; Jean-Marie Robine; Juliette Pinot; Jean-Jacques Arvieu; Joël Ankri Journal: Pharmacoepidemiol Drug Saf Date: 2015-04-08 Impact factor: 2.890
Authors: Kris M Jamsen; J Simon Bell; Sarah N Hilmer; Carl M J Kirkpatrick; Jenni Ilomäki; David Le Couteur; Fiona M Blyth; David J Handelsman; Louise Waite; Vasi Naganathan; Robert G Cumming; Danijela Gnjidic Journal: J Am Geriatr Soc Date: 2016-01 Impact factor: 5.562
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Kai-Uwe Saum; Ben Schöttker; Andreas D Meid; Bernd Holleczek; Walter E Haefeli; Klaus Hauer; Hermann Brenner Journal: J Am Geriatr Soc Date: 2016-12-26 Impact factor: 5.562
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: M Gutiérrez-Valencia; M Izquierdo; M Cesari; Á Casas-Herrero; M Inzitari; N Martínez-Velilla Journal: Br J Clin Pharmacol Date: 2018-05-03 Impact factor: 4.335
Authors: Christopher J D Threapleton; James E Kimpton; Iain M Carey; Stephen DeWilde; Derek G Cook; Tess Harris; Emma H Baker Journal: Br J Clin Pharmacol Date: 2020-03-16 Impact factor: 4.335
Authors: Shelley A Sternberg; Mirko Petrovic; Graziano Onder; Antonio Cherubini; Denis O'Mahony; Jerry H Gurwitz; Francesco Pegreffi; Robin Mason; Jennifer Akerman; Lisa McCarthy; Andrea Lawson; Joyce Li; Wei Wu; Paula A Rochon Journal: Eur Geriatr Med Date: 2021-04-09 Impact factor: 1.710